Immunotherapy before surgery leads to promising long-term survival in sarcoma patients
Patients with soft-tissue sarcoma treated with neoadjuvant, or pre-surgical, immunotherapy had very little residual tumor at the time of surgery and promising long-term survival, according to Phase II trial results published today in Nature Cancer by researchers at The University of Texas MD Anderson Cancer Center.
After treatment with a combination of immunotherapy and radiation followed by surgical removal of the residual...
